Chronic myeloid leukemia treatment with Imatinib: An experience from a private tertiary care hospital

The data presents 75 chronic myeloid leukemia patients diagnosed over a period 6 years i.e. from 2002 to 2008. The most common presentation was splenomegaly and 97% achieved complete hematological response at median duration of 4.3 weeks. The uniqueness of this study is follow-up with molecular resp...

Full description

Saved in:
Bibliographic Details
Main Authors: D C Doval, Ullas Batra, Sumit Goyal, Ajay Sharma, Saud Azam, Rashmi Shirali
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2013-01-01
Series:Indian Journal of Medical and Paediatric Oncology
Subjects:
Online Access:http://www.ijmpo.org/article.asp?issn=0971-5851;year=2013;volume=34;issue=3;spage=182;epage=185;aulast=Doval
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849699482569015296
author D C Doval
Ullas Batra
Sumit Goyal
Ajay Sharma
Saud Azam
Rashmi Shirali
author_facet D C Doval
Ullas Batra
Sumit Goyal
Ajay Sharma
Saud Azam
Rashmi Shirali
author_sort D C Doval
collection DOAJ
description The data presents 75 chronic myeloid leukemia patients diagnosed over a period 6 years i.e. from 2002 to 2008. The most common presentation was splenomegaly and 97% achieved complete hematological response at median duration of 4.3 weeks. The uniqueness of this study is follow-up with molecular response monitoring. Nearly, 30% patients achieved major molecular response (MMoR) by 12 months. 70% of patients achieved MMoR by median time of 60 months. Only 10% of the patient who achieved MMoR by 18 months had lost their responses subsequently.
format Article
id doaj-art-2fa479a8010b4c5fba8dc3522d4aa45b
institution DOAJ
issn 0971-5851
language English
publishDate 2013-01-01
publisher Thieme Medical and Scientific Publishers Pvt. Ltd.
record_format Article
series Indian Journal of Medical and Paediatric Oncology
spelling doaj-art-2fa479a8010b4c5fba8dc3522d4aa45b2025-08-20T03:18:34ZengThieme Medical and Scientific Publishers Pvt. Ltd.Indian Journal of Medical and Paediatric Oncology0971-58512013-01-0134318218510.4103/0971-5851.123725Chronic myeloid leukemia treatment with Imatinib: An experience from a private tertiary care hospitalD C DovalUllas BatraSumit GoyalAjay SharmaSaud AzamRashmi ShiraliThe data presents 75 chronic myeloid leukemia patients diagnosed over a period 6 years i.e. from 2002 to 2008. The most common presentation was splenomegaly and 97% achieved complete hematological response at median duration of 4.3 weeks. The uniqueness of this study is follow-up with molecular response monitoring. Nearly, 30% patients achieved major molecular response (MMoR) by 12 months. 70% of patients achieved MMoR by median time of 60 months. Only 10% of the patient who achieved MMoR by 18 months had lost their responses subsequently.http://www.ijmpo.org/article.asp?issn=0971-5851;year=2013;volume=34;issue=3;spage=182;epage=185;aulast=DovalChronic myeloid leukemiaDelhiImatinib
spellingShingle D C Doval
Ullas Batra
Sumit Goyal
Ajay Sharma
Saud Azam
Rashmi Shirali
Chronic myeloid leukemia treatment with Imatinib: An experience from a private tertiary care hospital
Indian Journal of Medical and Paediatric Oncology
Chronic myeloid leukemia
Delhi
Imatinib
title Chronic myeloid leukemia treatment with Imatinib: An experience from a private tertiary care hospital
title_full Chronic myeloid leukemia treatment with Imatinib: An experience from a private tertiary care hospital
title_fullStr Chronic myeloid leukemia treatment with Imatinib: An experience from a private tertiary care hospital
title_full_unstemmed Chronic myeloid leukemia treatment with Imatinib: An experience from a private tertiary care hospital
title_short Chronic myeloid leukemia treatment with Imatinib: An experience from a private tertiary care hospital
title_sort chronic myeloid leukemia treatment with imatinib an experience from a private tertiary care hospital
topic Chronic myeloid leukemia
Delhi
Imatinib
url http://www.ijmpo.org/article.asp?issn=0971-5851;year=2013;volume=34;issue=3;spage=182;epage=185;aulast=Doval
work_keys_str_mv AT dcdoval chronicmyeloidleukemiatreatmentwithimatinibanexperiencefromaprivatetertiarycarehospital
AT ullasbatra chronicmyeloidleukemiatreatmentwithimatinibanexperiencefromaprivatetertiarycarehospital
AT sumitgoyal chronicmyeloidleukemiatreatmentwithimatinibanexperiencefromaprivatetertiarycarehospital
AT ajaysharma chronicmyeloidleukemiatreatmentwithimatinibanexperiencefromaprivatetertiarycarehospital
AT saudazam chronicmyeloidleukemiatreatmentwithimatinibanexperiencefromaprivatetertiarycarehospital
AT rashmishirali chronicmyeloidleukemiatreatmentwithimatinibanexperiencefromaprivatetertiarycarehospital